Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Uterine
Study Phase
Phase 3
Study Completion Date
2009
NCT01012297Uploaded 08-21-2020
Access via NCI by Request
PDS UID: nci-data-422
N/A
Provider Information
Provider Data DescriptionThis dataset will allow users to reproduce the treatment comparison between Gemcitabine Plus Docetaxel Plus Bevacizumab and Gemcitabine Plus Docetaxel Plus Placebo
SponsorNational Cancer Institute (NCI)
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryN/A
ConditionsN/A
Intervention TypeDrug, Placebo
Drug(s)N/A
Total EnrolledN/A
RandomizationN/A
Blinding MethodN/A
Arms InterventionN/A
Secondary IDN/A
PubMed (PMID)N/A
Collaborator(s)N/A
Region(s)N/A
Age RangeN/A
Files: NCT01012297-D1
Data DictionaryNCT01012297-D1-Data-Dictionary_3.pdf
DATANCT01012297-D1-Dataset_2.csv
OTHERREADME.pdf
© 2023 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use